MAIA Biotech announces trial design to expand THIO-101 Phase 2 NSCLC study

MAIA Biotechnology (MAIA) announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer NSCLC . Following successful outcomes to date in THIO-101, the expansion of the study will assess overall response rates ORR in advanced NSCLC patients receiving third line 3L therapy who were resistant to previous checkpoint inhibitor treatments CPI and chemotherapy…MAIA recently announced an amended clinical supply agreement with Regeneron to include the expansion portion of THIO-101. Under terms of the amended agreement, MAIA continues to sponsor THIO-101 and Regeneron will provide Libtayo for the treatment of all patients including the additional patients in the expansion and potentially, the registration studies. ..”We have multiple milestones that we believe are attainable for 2025 and we look forward to keeping our shareholders and investors well informed of our progress on value creation,” Dr. Vitoc added. As of January 15, data indicated that Median Overall Survival OS in third-line treatment was reached at 16.9 months, with a 95% confidence interval CI lower bound of 12.5 months and a 99% CI lower bound of 10.8 months . The treatment has been generally well-tolerated to date in this heavily pre-treated population .